Bioxytran Q2 net loss turns to $619,929; H1 net loss widens to $2.69 millionPUBT·Aug 14 at 08:13 PMBIXT+3.96%
Bioxytran reports functional gains in first CIDP patient treated with PLICID galectin antagonistPUBT·Aug 11 at 11:01 AMBIXT+3.96%
Bioxytran says Phase 2 trial of ProLectin-M drives SARS-CoV-2 viral load below detection by day sevenPUBT·Aug 4 at 11:05 AMBIXT+3.96%
BIOXYTRAN, INC 1Q 2026: Net loss $(2.07M), EPS $(0.02) — 10-Q SummaryTradingView·May 15 at 05:31 PMBIXT+3.96%
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization | NRXBF Stock NewsStockTitan·Apr 7 at 05:20 AMABCL-1.21%XBI-0.35%
Bioxytran Raises Capital to Advance Development and CommercializationTip Ranks·Mar 20 at 01:33 PMBIXT+3.96%
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT | BIXT Stock NewsStockTitan·Mar 20 at 05:05 AMBIXT+3.96%
Bioxytran Reports Positive Dose Optimization Results, Advances ProLectin-M Toward Phase 3 Trialrttnews·Mar 5 at 07:00 AMBIXT+3.96%
Bioxytran sees positive dose optimization, moves to Phase 3 trial for ProLectin-M with 408 patients, targeting viral infected outpatients.Unusual Whales·Mar 4 at 08:42 PMBIXT+3.96%
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M | BIXT Stock NewsStockTitan·Mar 4 at 12:40 PMBIXT+3.96%
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 | BIXT Stock NewsStockTitan·Mar 2 at 08:40 AMBIXT+3.96%
